세계의 바이오칩 시장 보고서 : 제품 유형, 제조 기술, 분석 방법, 용도, 최종 사용자 및 지역별(2024-2032년)

The global biochips market size reached US$ 19.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 64.3 Billion by 2032, exhibiting a growth rate (CAGR) of 13.7% during 2024-2032. The market is experiencing steady growth driven by innovations in next-generation sequencing and lab-on-a-chip technologies to enhance biochip capabilities, substantial funding from governments and private sectors for genetic and molecular research, and the increasing demand for personalized medicine.

Biochips Market Analysis:

Major Market Drivers: Advances in technology and subsequent innovations in the technology of biochips greatly fuel the market. Additionally, the rise in sensitivity, accuracy, and miniaturization is also driving the demand for these chips. Other prominent drivers for the market include rising demand for personalized medicine and augmented investment in genomics and proteomics research.

Key Market Trends: The integration of biochip technology with AI and ML algorithms is one such key trend. It is facilitating the development of precision medicine, drug discovery, and diagnostics with enhanced accuracy. This can be supported by shifting personalized and preventive treatment patterns towards the adoption of biochips for highly detailed molecular analyses and targeted therapeutic interventions.

Geographical Trends: According to the biochips market research report, North America represents an increasing biochips market share driven by heavy investment in health care and biotechnology research. Asia-Pacific is rapidly growing, impelled by increasing expenditure on healthcare and a rising focus on precision medicine in countries such as China and India.

Competitive Landscape: The market is quite a competitive space where key players are investing in research and development to offer platform innovations into the market. Concurrently, the major players are entering strategic collaborations, mergers, and acquisitions to get an upper hand on technological expertise and geographical presence. Some of the major market players in the biochips industry include Agilent Technologies, Inc., bioMerieux SA, Bio-RAD Laboratories, Inc., CapitalBio Corporation, Dynamic Biosensors GmbH, EMD Millipore Corporation, Fluidigm Corporation, Illumina, Inc., Perkinelmer, Inc., and Thermo Fisher Scientific Inc., among many others.

Challenges and Opportunities: The high cost associated with biochip technology, and the regulatory framework, particularly in certain countries, is complex, hence the major challenges to the growth of this market. Opportunities are related to the extension of applications of biochips in fields with fast development, such as agriculture, forensic sciences, and environmental monitoring, coupled with the continuous development of biochip technology.

Biochips Market Trends:

Technological advancements and innovations

The market is propelled by the rapid progress in technology and periodic modifications of biochip technologies. Biochips are transforming, such as the next-generation sequencing (NGS), lab-on-a-chip, and microarray technologies that improve the power and effective performance of biochips. Further, the advent of biochip-based solutions that are integrated with artificial intelligence (AI) and machine learning (ML) algorithms is amplifying precision medicine, drug discovery, and diagnostic-related applications. Biochips are becoming essential tools as they change to greater sensitivity, accuracy, and miniaturization in genomics, proteomics, and other molecular biology fields, which is enhancing biochips market value. Additionally, ongoing initiatives being taken by the prominent industry players in terms of R&D to launch advanced biochip products and solutions that could respond effectively to emerging requirements from healthcare and biotechnology verticals further fuel market expansion.

Growing demand for personalized medicine

The increasing demand for personalized medicine also significantly fuels the market. Personalized medicine as a practice based on individual profiling of patients by genetic, environmental, and lifestyle factors in tailoring treatment plans is accelerating the need for technologies related to biochips. In addition, the requirement for advanced diagnostic tools such as biochips is growing with the healthcare sector rapidly shifting towards personalized and preventive medicine. This trend can be supported by an increase in the incidence of chronic diseases such as cancer and cardiovascular disorders, which need detailed molecular insight for effective management. Thus, due to the growing scope of personalized medicine, biochips continue to get greater acceptance in clinical and research settings which is further creating a positive biochips market outlook.

Increasing investment in genomics and proteomics research

One of the key drivers for the global market of biochips is increasing investments in genome and proteome research. All governments, academic institutions, and private sectors are investing in genomic as well as proteomic studies, to understand complex biological systems and devise innovative health solutions. Biochips find large applications since they permit high-throughput analysis and large-scale studies of various interactions, such as genetically or proteomically. In addition, the growing applications in precision agriculture, forensic sciences, and environmental monitoring, among others, where high-throughput molecular analyses are required. Moreover, the demand for sophisticated biochip platforms is rising as globally growing funding and collaborative research continue to broaden the scope of this market, thus directing it to foster ongoing new life sciences research.

Biochips Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biochips market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, fabrication technique, analysis method, application, and end user.

Breakup by Product Type:

DNA Chip

Protein Chip

Lab-On-a-Chip

Enzyme Chip

DNA Chip represents the largest market segment

The report has provided a detailed breakup and analysis of the biochips market based on the product type. This includes DNA chip, protein chip, lab-on-a-chip, and enzyme chip. According to the report, DNA chip represented the largest segment.

DNA chips, otherwise called DNA microarrays, are currently the largest product type in the market. This can be supported by the wide application spectrum and technological advances. These chips facilitate large-scale analyses of genetic information; such chips become core tools in genomics, diagnostics, and personalized medicine. Thousands of genes can be analyzed simultaneously, hence making landmark changes in research related to cancer genomics, genetic disorder screening, and pharmacogenomics. It is resulting in more sensitive, specific, and efficient DNA chips with upgraded technologies, thereby increasing adoption. According to the biochips market report, the growing interest in precision medicine and health treatments by individual genomics also accelerates the demand for DNA chips. Key players in the marketplace are engaged in extensive research and development to come up with new products in DNA chips, thereby helping the changing requirements of healthcare and biotech companies. Apart from this, increasing incidences of genetic disorders and chronic diseases require detailed genetic profiling, and thus, DNA chips assume a significant role in contemporary diagnostics and therapy. DNA chips, therefore, hold a greater share in the biochips market since they represent a vital constituent in promoting molecular biology and individualistic healthcare solutions.

Breakup by Fabrication Technique:

Microarray

Microfluidic

Microarray represents the largest market segment

A detailed breakup and analysis of the biochips market based on the fabrication technique has also been provided in the report. This includes microarray and microfluidic. According to the report, microarray accounted for the largest market share.

Microarray technology is the most widely used fabrication technique in this market due to its versatility and efficiency for different applications. This method permits large amounts of biological data to be analyzed at the same time and is used in genomics, transcriptomics, and proteomic studies. The biochips market forecast suggests that quantification of gene or protein expression across the spectrum in a single experiment is game-changing for drug discovery, disease diagnosis, and personalized medicine. New microarray technologies support more accurate, faster, and scaled-up biochip fabrication to enable reliable detection over large fractions of the corresponding user population. Microarray technology is widely used in the healthcare and bioinformatics sectors to improve research activities, as well as help introduce new targeted therapies. Additionally, their integration with modern data analysis techniques and bioinformatics platforms is further expanding the use of microarrays for understanding complex biological processes. With the growth of personalized medicine, the coming years will see a great increase in demand for accurate and high-throughput analytical platforms such as microarrays. Hence, microarray technology continues to be the leading method of manufacturing in the marketplace and plays a foundational role in propelling biomedical research forward as well as improving clinical diagnostics.

Breakup by Analysis Method:

Electrophoresis

Luminescence

Mass Spectrometry

Electrical Signals

Magnetism

Electrophoresis represents the largest market segment

A detailed breakup and analysis of the biochips market based on the analysis method has also been provided in the report. This includes electrophoresis, luminescence, mass spectrometry, electrical signals, and magnetism. According to the report, electrophoresis accounted for the largest market share.

Electrophoresis is the most dominant method of analysis in biochips due to its wide applicability, strength, and precision in separation techniques, and the analysis of biological molecules. This also represents a vital technique in functional genomics, proteomics, and molecular biology through the effective separation of DNA, RNA, and proteins, based on size and charge, offering a view into their structure and function. According to the biochips market overview, electrophoresis is being utilized in several research and routine laboratories, especially in tasks related to genetic mapping, disease diagnosis, and forensic analysis. This, in addition to being a robust and accurate system, permitted working in unison with advanced biochip technologies to ensure better resolution and higher throughput of molecular analyses. Electrophoresis techniques, including capillary and microfluidic electrophoresis, have recently been innovated to further enhance its operations, moving faster and offering more detailed examinations. Evident through the increasing need for high-precision analytical tools within the fields of personalized medicine and biotechnology, electrophoresis is set to remain prominent. Moreover, it consolidates a central position as the leading analysis method in the market with the escalating complex biological systems and disease mechanisms.

Breakup by Application:

Molecular Analysis

Hybridization

Protein

Immunological

Biomolecules

Biomarker

Others

Diagnosis

Gene Diagnosis

Oncology

Inflammatory

Others

Non-Biological Usage

Diagnosis represents the largest market segment

A detailed breakup and analysis of the biochips market based on the application has also been provided in the report. This includes molecular analysis (hybridization, protein, immunological, biomolecules, biomarker, and others), diagnosis (gene diagnosis, oncology, inflammatory, and others), and non-biological usage. According to the report, diagnosis accounted for the largest market share.

Diagnosis is the largest application in the market as an accurate, fast, and comprehensive diagnostic tool is necessary in healthcare. Biochips are revolutionizing the concept of diagnosis in that they can analyze multiple biomarkers in a single chip, helping in the early and accurate detection of diseases. Therefore, this is escalating the biochips demand. This is important in managing chronic and infectious diseases, such as cancer, cardiovascular disorders, and emerging viral infections. These factors are leading to the integration of biochips in diagnostic platforms, which further resulted in enhanced specificity and sensitivity of tests, thereby leading toward better patient outcomes, based on test results, through timely and targeted interventions. Apart from this, progress in biochip technology in the form of microarrays and lab-on-a-chip systems has made things easier, cost-effective, and more accessible at the diagnostic level. The stakes for diagnostics based on biochips are further raised by the rise of personalized medicine, as these will be able to render analyses of genetic profiles to administer treatments on an individual basis. With the changing landscape of healthcare across the globe toward precision and preventive medicine, the adoption of biochips for diagnostic purposes is gaining considerable ground, which essentially sets this as a cornerstone in modern medical diagnostics and fuels the biochips market growth.

Breakup by End User:

Pharmaceutical and Biotechnology Companies

Hospitals and Diagnostics Centers

Academic and Research Institutes

Others

Pharmaceutical and biotechnology companies represent the largest market segment

A detailed breakup and analysis of the biochips market based on the end user has also been provided in the report. This includes pharmaceutical and biotechnology companies, hospitals and diagnostics centers, academic and research institutes, and others. According to the report, pharmaceutical and biotechnology companies accounted for the largest market share.

The largest end users in the biochips industry are pharmaceuticals and biotechnology firms. This can be attributed to their extensive research and development activities and increased demand for new and fresh solutions in drug discovery and development processes. Biochips help these sectors immensely in areas such as high-throughput screening, gene analysis, and biomarker identification for the comprehension of the mechanisms of diseases and the subsequent development of targeted therapies. Additionally, biochip technology makes possible new technologically precise, faster, and less expensive methods that hasten drug development and inform and facilitate the planning of clinical trials, hence putting personalized medicine into action with detailed molecular insight. In regard to this, the heavy investments in biochip technology by the studied firms is to improve efficiency and lower development costs. Moreover, close collaboration between the manufacturers of biochips and pharmaceutical and biotech companies fosters further improved forms of biochips tailored to special research needs. With continued pressure from the rising need for new therapeutics and personalized treatment options, there is a growing reliance on biochips within these industries, and it can create a critical difference in innovating and building a competitive edge to deal with the transforming environment of healthcare.

Breakup by Region:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Spain

Russia

Italy

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Others

Latin America

Mexico

Brazil

Argentina

Others

Middle East and Africa

Turkey

Saudi Arabia

United Arab Emirates

Others

North America leads the market, accounting for the largest biochips market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Spain, Russia, Italy, and others); Asia Pacific (China, India, Japan, South Korea, Australia, and others); Latin America (Mexico, Brazil, Argentina, and others); and the Middle East and Africa (Turkey, Saudi Arabia, United Arab Emirates, and others). According to the report, North America represents the largest regional market for biochips.

The North America region is the largest contributor to the biochips market due to high-quality healthcare infrastructure and substantial investments in biotechnology research, followed by Asia-Pacific being robustly driven by technological innovation. Besides, the sovereignty of this region is also driven by some major market players in biotech, such as Samsung Biologics and Celltrion, along with comprehensive government support for R&D activities. Along with this, rising chronic diseases and personalized medicine requirements are further fueling a rise in the usage of biochip technologies. Prospective growth opportunities for this market in major countries such as the U.S. and Canada are propelling regional expansion due to genomics and proteomics research grants which are augmenting the biochips market revenue. In addition, the presence of mature pharmaceutical and biotechnology industries in North America allows expeditious commercialization and adoption of biochip applications across diverse healthcare settings.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the biochips industry include:

Agilent Technologies, Inc.

bioMerieux SA

Bio-RAD Laboratories, Inc.

CapitalBio Corporation

Dynamic Biosensors GmbH

EMD Millipore Corporation

Fluidigm Corporation

Illumina, Inc.

Perkinelmer, Inc.

Thermo Fisher Scientific Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The leading biochips companies are engaged in research and development with respect to new products and technological innovations to enhance the existing technology. Major companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies execute next-generation sequencing and lab-on-chip systems. This develops sensitivity, accuracy, and throughput, hence meeting demand for precise diagnostic and research tools. Such strategic collaborations, mergers, and acquisitions often allow these firms to develop their product line and increase their geographical presence. They are also integrating the biochip technology with artificial intelligence and machine learning, which enhances the data analysis capability. These major players, therefore, meet changing requirements in personalized medicine, diagnostics, and drug discovery, hence maintaining a competitive edge and accelerating the market growth.

Biochips Market News:

September 4, 2023: Agilent and ACTRIS announced their collaboration to expedite cellular and genetic treatment in Singapore. The new partnership intends to install and operate Agilent's xCELLigence real-time cell analyzer, Seahorse XF technology, and other cell analysis portfolio in the country's largest national cell and gene therapy process development and manufacturing facility at ACTRIS.

August 17, 2023: Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the opening of a new office as well as a state-of-the-art Illumina Solutions Center (ISC) to support the growing customer base in Bengaluru.

Key Questions Answered in This Report:

• How has the global biochips market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global biochips market?
• What is the impact of each driver, restraint, and opportunity on the global biochips market?
• What are the key regional markets?
• Which countries represent the most attractive biochips market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the biochips market?
• What is the breakup of the market based on the fabrication technique?
• Which is the most attractive fabrication technique in the biochips market?
• What is the breakup of the market based on the analysis method?
• Which is the most attractive analysis method in the biochips market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the biochips market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the biochips market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global biochips market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Biochips Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 DNA Chip
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Protein Chip
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Lab-On-a-Chip
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Enzyme Chip
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Fabrication Technique

• 7.1 Microarray
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Microfluidic
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Analysis Method

• 8.1 Electrophoresis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Luminescence
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Mass Spectrometry
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Electrical Signals
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Magnetism
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Application

• 9.1 Molecular Analysis
  • 9.1.1 Hybridization
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Protein
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
  • 9.1.3 Immunological
    • 9.1.3.1 Market Trends
    • 9.1.3.2 Market Forecast
  • 9.1.4 Biomolecules
    • 9.1.4.1 Market Trends
    • 9.1.4.2 Market Forecast
  • 9.1.5 Biomarker
    • 9.1.5.1 Market Trends
    • 9.1.5.2 Market Forecast
  • 9.1.6 Others
    • 9.1.6.1 Market Trends
    • 9.1.6.2 Market Forecast
• 9.2 Diagnosis
  • 9.2.1 Gene Diagnosis
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Oncology
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 Inflammatory
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 Others
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
• 9.3 Non-Biological Usage
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by End User

• 10.1 Pharmaceutical and Biotechnology Companies
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hospitals and Diagnostics Centers
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Academic & Research Institutes
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Europe
  • 11.2.1 Germany
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 France
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 United Kingdom
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 Spain
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Russia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Italy
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Asia Pacific
  • 11.3.1 China
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 India
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 Japan
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 South Korea
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Australia
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Others
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Mexico
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Brazil
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Argentina
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
  • 11.4.4 Others
    • 11.4.4.1 Market Trends
    • 11.4.4.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Turkey
    • 11.5.1.1 Market Trends
    • 11.5.1.2 Market Forecast
  • 11.5.2 Saudi Arabia
    • 11.5.2.1 Market Trends
    • 11.5.2.2 Market Forecast
  • 11.5.3 United Arab Emirates
    • 11.5.3.1 Market Trends
    • 11.5.3.2 Market Forecast
  • 11.5.4 Others
    • 11.5.4.1 Market Trends
    • 11.5.4.2 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agilent Technologies, Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 bioMerieux SA
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bio-RAD Laboratories, Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 CapitalBio Corporation
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Dynamic Biosensors GmbH
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 EMD Millipore Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Fluidigm Corporation
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Illumina, Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Perkinelmer, Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Thermo Fisher Scientific, Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis